Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir
| Autor: | M. Strobel, S. Herson, J. M. Lang, C. Picard-Dahan, Bruno Hoen, Dominique Salmon, Eric Billaud, P. Elinger, A. Laffeuillade, J. L. Touraine, M. Bentata, Renaud Verdon, Christine Katlama, P. Honoré, Claudine Duvivier, Sophie Abgrall, E. Arlet-Suau, K. Aleksandrowicz, Christian Trepo, Pascal Pugliese, T. Allegre, Jacques Gasnault, Jean-Pierre Daurès, C. Gaud, Xavier Duval, Emilie Lanoy, Anne Frésard, D. Quinsat, Valérie Potard, Jean-Pierre Clauvel, Jean-Michel Molina, J. M. Livrozet, P. Lecercq, B. Crickx, Elisabeth Bouvet, Hervé Tissot-Dupont, Y. Yasdanpanah, H. Laurichesse, M. Nezri, Christian Pradier, M. Brosseau, M. F. Maître, N. Desplanque, J. P. Delmont, Sophie Matheron, F. Lucht, D. Tisne-Dessus, Dominique Costagliola, François Raffi, P. De Truchis, Pierre Dellamonica, M. F. Thiercelin Legrand, Jean-Marc Lacombe, J. Soubeyrand, A. Simon, Cécile Goujard, E. Mortier, Isabelle Poizot-Martin, Hana Selinger-Leneman, Isabelle Ravaux, C. Jung, P. Sellier, Jean-Paul Viard, Christian Michelet, T. May, I. Auperin, J. L. Ecobichon, Valérie Martinez, J. P. Faller, P. Granet-Brunello, François Caron, M. Contant, Jean-Luc Berger, Laurence Lievre, Jacques Cadranel, Marie-Caroline Meyohas, C. Mayaud, Jacques Moreau, P. Choutet, André Boibieux, Patricia Enel, G. Beck-Wirth, Laurence Gérard, R. Pradinaud, Elisabeth Rouveix, M. Sobesky, H. Berthé, Francis Barin, J. M. Decazes, A. Galinier, Jacques Reynes, R. Cohen-Valensi, Patrick Yeni, T. Bommenel, Jean-Paul Stahl, C. Bazin, Vincent Jeantils, Pierluigi Blanc, Laurence Weiss, Daniel Vittecoq, Laurent Cotte, Pierre Tattevin, G. Pontonnier, David Rey, Sophie Grabar, Christian Rabaud, M. Diemer, D. Peyramond, Marguerite Guiguet, Pierre-Marie Girard, F. Pilorgé, S. Chapadaud, Jacques Gilquin, N. Jacquemet, Odile Launay, C. Chandemerle, P. Lesprit, Aba Mahamat, B. Taverne, F. Borsa-Lebas, G. Lepeu, Pascal Chavanet, Juliette Pavie, F. Gourdon, Jean-Albert Gastaut, Jean-François Delfraissy, Odile Picard, R. Fior, Alain Goudeau, P. Fraisse, M. A. Khuong, Lise Cuzin, Murielle Mary-Krause, L. Roudière, Boue F, V. Salomon, J. P. Esterni, N. Viget, D. Bonnet-Montchardon, Cédric Arvieux, André Cabié, Gilles Pialoux, François Bricaire, Jean-Luc Meynard, S. Tassi, Patrice Massip, Caroline Dupont, Christine Burty, F. Retornaz, D. Mechali, G. Rémy, Anne-Sophie Lascaux, L. Pelissier, J. M. Ruiz, F. Bissuel |
|---|---|
| Přispěvatelé: | Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC - Biotherapie - AP-HP (cochin - Pasteur), Institut National de la Santé et de la Recherche Médicale (INSERM), Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôtel-Dieu, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu, Service d'immunologie clinique [Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service des maladies infectieuses, Hopital Andree Rosemond, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Cytokines, chimiokines et immunopathologie, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Public Health Department, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice (CHU Nice), Service de Médecine Interne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), FHDH-ANRS CO4, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA) |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Cyclopropanes
Male HIV Infections boosted protease inhibitor MESH: Antiretroviral Therapy Highly Active Cohort Studies chemistry.chemical_compound 0302 clinical medicine Abacavir immune system diseases Antiretroviral Therapy Highly Active Pharmacology (medical) 030212 general & internal medicine Prospective Studies MESH: Anti-HIV Agents MESH: Nevirapine MESH: Cohort Studies MESH: Treatment Outcome 0303 health sciences MESH: HIV Hazard ratio virus diseases MESH: HIV Infections Viral Load switch 3. Good health Infectious Diseases Treatment Outcome MESH: Dideoxynucleosides [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology Alkynes MESH: Benzoxazines HIV/AIDS Female MESH: Viral Load Viral load medicine.drug Microbiology (medical) Cart Adult medicine.medical_specialty Efavirenz Nevirapine Anti-HIV Agents 03 medical and health sciences Internal medicine parasitic diseases medicine cohort study Humans MESH: HIV Protease Inhibitors Pharmacology MESH: Humans 030306 microbiology business.industry HIV MESH: Adult HIV Protease Inhibitors Virology Confidence interval Dideoxynucleosides MESH: Male MESH: Prospective Studies Benzoxazines Regimen chemistry business MESH: Female virological effectiveness |
| Zdroj: | Journal of Antimicrobial Chemotherapy Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2011, 66 (8), pp.1869-77. ⟨10.1093/jac/dkr208⟩ Journal of Antimicrobial Chemotherapy, 2011, 66 (8), pp.1869-77. ⟨10.1093/jac/dkr208⟩ |
| ISSN: | 0305-7453 1460-2091 |
| Popis: | International audience; OBJECTIVES: To compare virological effectiveness in patients who continued on a virologically successful first-line boosted protease inhibitor (PI)-containing combination antiretroviral therapy (cART) regimen or who switched to a PI-free cART including efavirenz, nevirapine or abacavir. METHODS: From the French Hospital Database on HIV, we selected 439 patients with undetectable viral load (VL) on a first-line boosted PI-containing cART regimen who switched to a PI-free combination including efavirenz, nevirapine or abacavir. Each of these patients was matched with three patients who continued to take their first-line cART regimen, on the basis of gender, age, CD4 cell count, VL, date of cART initiation and the duration of VL undetectability. Time to virological failure (VF) was analysed with Kaplan-Meier curves and Cox models. RESULTS: The 12 month probabilities of VF were 3.7% and 5.7% in non-switch and switch patients, respectively, and 3.9%, 7.2% and 9.0% in patients switching to efavirenz-, nevirapine- and abacavir-containing cART, respectively. After adjustment, only patients switching to abacavir-containing cART had a higher risk of VF than non-switch patients (adjusted hazard ratio, 1.99; 95% confidence interval, 1.05-3.79). CONCLUSIONS: Switching from a virologically successful first-line boosted PI-containing cART regimen to a non-nucleoside reverse transcriptase inhibitor-containing cART regimen containing either efavirenz or nevirapine is virologically safe, while switching to abacavir-containing cART should be avoided. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|